Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Adnexus Therapeutics Announces Additional Phase I and Preclinical Data on CT-322 at 6th International Congress on Targeted Therapies in Cancer
Adnexus Therapeutics Files Registration Statement for Proposed Initial Public Offering
Adnexus Therapeutics Announces Appointment of Timothy J. Rink, MD, ScD to Its Board of Directors
Adnexus Therapeutics to Present Data on Adnectin Product Candidate, CT-322, at Gordon Research Conference
Adnexus Therapeutics Raises $15.5 Million in Series C Funding
Adnexus Therapeutics Appoints Martin Freed, MD as Chief Medical Officer
Adnexus Therapeutics Announces Presentation at The American Association For Cancer Research (AACR) on Clinical Product Candidate, CT 322
Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds
Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
Adnexus Therapeutics to Present at Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6th
Adnexus Therapeutics Announces Issuance of U.S. Patent For Broad Protection of New Therapeutic Class, Adnectins™
Adnexus Therapeutics Appoints L. Patrick Gage, PH.D., As Chairman Of The Board Of Directors
Adnexus Therapeutics To Present At UBS Global Life Sciences Conference On Tuesday, September 26
Adnexus Therapeutics to Present at Thomas Weisel Partners Healthcare Conference
Adnexus Therapeutics Awarded SBIR Grant for Adnectin Research
Adnexus Therapeutics Expands and Strengthens Senior Management Team
Adnexus Therapeutics Closes $27M Series B Funding
First Adnectin Therapeutic, CT-322, Clears FDA IND Review To Start Clinical Trials
Compound Therapeutics Becomes Adnexus Therapeutics
Compound Therapeutics Announces Initiation of IND-Enabling Safety Studies With Lead Oncology Product
Compound Therapeutics Appoints Dr. John Mendlein as CEO
Compound Therapeutics, Inc. Raises $15.5 Million To Advance Product Pipeline Into Clinic
Paul Kidwell Suda Communications 617.296.3854 paulkidwell@comcast.net
